CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BDTX

silevertinib in combination with temozolomide

Phase 2
Black Diamond Therapeutics, Inc. (BDTX)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Glioblastoma (GBM)

View Full Landscape
Drug Information

Target Indication

Glioblastoma (GBM)

Clinical Trial

NCT07326566

Last updated: 3/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.